Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Another Denosumab Deal For mAbxience In MEA

MS Pharma Is Set To Register And Market The Prolia/Xgeva Biosimilar In MEA Markets

15 Nov 2023

• By Dave Wallace

View of Earth highlighting middle east and Africa — MS Pharma will market mAbxience’s denosumab in MEA territories • Source: Shutterstock

Related Content

HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal

31 Jan 2023

Amneal And mAbxience Ally On Denosumab In US

13 Oct 2023

Mabxience Sets Out Investment Plans Under Fresenius Ownership

11 Apr 2023

MS Pharma Partners With Mabxience For Bevacizumab In MENA Region

31 Aug 2021

Abbott To Take mAbxience Biosimilars To Emerging Markets From 2025

20 Sep 2023

Related Companies

mAbxience S.L.

Additional Topics

Middle East and Africa Deals Biosimilars BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.